Veradigm (MDRX) Competitors

Veradigm (NASDAQ:MDRX) and Omnicell (NASDAQ:OMCL) are both small-cap health care technology companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

Does the media refer more to MDRX or OMCL?

In the previous week, Omnicell had 4 more articles in the media than Veradigm. MarketBeat recorded 4 mentions for Omnicell and 0 mentions for Veradigm. Omnicell's average media sentiment score of 0.59 beat Veradigm's score of 0.55 indicating that Omnicell is being referred to more favorably in the news media.

Company	Overall Sentiment
Veradigm	Positive
Omnicell	Positive

Is MDRX or OMCL more profitable?

Omnicell has a net margin of 2.01% compared to Veradigm's net margin of 0.00%. Omnicell's return on equity of 4.27% beat Veradigm's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veradigm	N/A	N/A	N/A
Omnicell	2.01%	4.27%	2.44%

Which has stronger earnings & valuation, MDRX or OMCL?

Omnicell has lower revenue, but higher earnings than Veradigm.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradigm	$1.53B	0.34	N/A	N/A	N/A
Omnicell	$1.11B	1.28	$12.53M	$0.50	61.78

Which has more volatility and risk, MDRX or OMCL?

Veradigm has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500. Comparatively, Omnicell has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500.

Do analysts recommend MDRX or OMCL?

Veradigm presently has a consensus target price of $13.00, suggesting a potential upside of 173.68%. Omnicell has a consensus target price of $46.71, suggesting a potential upside of 51.23%. Given Veradigm's higher possible upside, analysts plainly believe Veradigm is more favorable than Omnicell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradigm	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Omnicell	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

Do institutionals and insiders have more ownership in MDRX or OMCL?

97.7% of Omnicell shares are held by institutional investors. 2.3% of Veradigm shares are held by insiders. Comparatively, 2.5% of Omnicell shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Omnicell beats Veradigm on 11 of the 13 factors compared between the two stocks.